🔗 Share this article

As the United States continues making historic changes to its vaccination guidelines, one figure has emerged in a surprising turn: Høeg, a Danish American physician and epidemiologist who rose to prominence by casting doubt on Covid vaccinations throughout the global health crisis and has focused upon alleged deaths after COVID-19 immunization in her short time at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Immunization Program

Agency leaders were set to announce sweeping changes to the childhood immunization program recently, synchronizing the US with Denmark’s national calendar, sources say – a significant shift that would put the US out of step with much of the international standard with insufficient data for public health gain. The announcement has been postponed until the next year.

Rather than the director of the vaccine center, Dr. Høeg is scheduled to speak at the event. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the office this calendar year.

A Shift at the Agency

This interim role might represent a tighter collaboration between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad solidify control at the agency – and it points to a greater focus upon dismantling long-standing vaccines at the FDA.

Dr. Høeg has repeatedly called for ending specific pediatric vaccine recommendations in the US so as to align more similar to Denmark's approach, a society with comprehensive healthcare and a population roughly the population of the state of Wisconsin.

To date statements, she has continued to focus on vaccination policy – traditionally the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Questions Over Expertise

The appointee has no obvious experience in medication creation, oversight or leadership, which has been standard for former heads of the CBER. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for running the CDER, stated a neurologist and psychiatrist. “She’s never run a scientific study. She has no expertise in managing a large organization. She lacks background in drug approvals.”

Past directors of the center would “be deeply familiar with regulatory frameworks and the research of medication creation”, commented a former acting FDA commissioner. “Objectively, she doesn’t have the sort of resume that previous people who headed the center have had.”

This division has an vast range of responsibilities at the FDA, the former commissioner stated.

“Many people just zeroes in on the new drug program, but the generic drug division clears a multitude of generic drugs. There is also a biosimilars division, OTC medication office and more, and each of these need to be managed,” she said. “The area you overlook, that is the part that I always told people is going to cause problems.”

There is also, a major management component to the role, which manages in excess of 5,000 employees. “It’s a enormous management job, if you do it right,” she said.

Response and Controversial Policies

Regarding concerns about Høeg’s fitness for the role and whether this appointment represents increased cooperation among regulatory chiefs on immunizations, a representative stated that the “inquiries stem from flawed assumptions”.

“Her experience is consistent with the functions of her job,” the official stated, noting the period Dr. Høeg spent guiding the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a contentious expedited therapy clearance system that allegedly concerned her predecessors. “How are these drugs being picked for this expedited pathway? Who is making the calls?” Howard asked. “There’s a lot of lack of transparency happening at the regulatory body right now.”

In general, he remarked, “the agency appears to be shifting towards laxer regulations of most medications, except for immunizations.”

Public Track Record on Immunizations

With immunizations, Dr. Høeg has a more established, if concerning, track record, Howard observe. She published a analysis using unconfirmed crowd-sourced reports to determine the frequency of myocarditis after Covid immunization. She consulted for the Florida surgeon general Joseph Ladapo, who allegedly have altered data to indicate Covid vaccines are pose a greater threat than they are.

Included in her “policy goals” for the new federal leadership featured revising rules for new vaccines and discontinuing “optional” immunizations, she said following the vote on a audio program. At the FDA, Dr. Høeg has reportedly suggested barring adolescent males from receiving Covid vaccinations.

“She’s an all-around dogmatist who begins with her preconceived notions and reverse-engineers to accommodate the evidence in a highly misleading, untruthful way,” Dr. Howard stated.

Gaining Influence and a “Push for Payback”

Høeg aligned with other contrarians, {like|